Literature DB >> 28895202

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

A Nast1, P I Spuls2, G van der Kraaij2, P Gisondi3, C Paul4, A D Ormerod5, P Saiag6, C H Smith7, E Dauden8, E M de Jong9, E Feist10, R Jobling11, M Maccarone12, U Mrowietz13, K A Papp14, K Reich15, S Rosumeck1, T Talme16, H B Thio9, P van de Kerkhof9, R N Werner1, C Dressler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28895202     DOI： 10.1111/jdv.14454

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  32 in total

Review 1.  Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

2.  Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria.

Authors:  Paul Sator; Robert Loewe; Omid Zamani; Gregor Holzer; Peter Wolf; Alexander Mlynek; Thomas Berger; Leo Richter; Elisabeth Schuller
Journal:  Wien Klin Wochenschr       Date:  2019-10-07       Impact factor: 1.704

Review 3.  Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.

Authors:  Donovan G Kearns; Shelley Uppal; Vipawee S Chat; Jashin J Wu
Journal:  J Clin Aesthet Dermatol       Date:  2021-06-01

4.  Prescription Behaviour and Barriers to Prescription of Biologicals for Treatment of Chronic Inflammatory Skin Diseases in Dermatological Practice in Two German Federal States.

Authors:  Daniela Weiss; Imke Nordhorn; Linda Tizek; Thomas Werfel; Alexander Zink; Tilo Biedermann; Stephan Traidl; Maximilian C Schielein
Journal:  Acta Derm Venereol       Date:  2021-09-28       Impact factor: 3.875

5.  Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience.

Authors:  Pau Rosés Gibert; Francisco Javier de la Torre Gomar; Amaia Saenz Aguirre; Javier Gimeno Castillo; Ricardo González Pérez
Journal:  Psoriasis (Auckl)       Date:  2022-06-29

6.  A Rasch model analysis of two interpretations of 'not relevant' responses on the Dermatology Life Quality Index (DLQI).

Authors:  Fanni Rencz; Ariel Z Mitev; Ákos Szabó; Zsuzsanna Beretzky; Adrienn K Poór; Péter Holló; Norbert Wikonkál; Miklós Sárdy; Sarolta Kárpáti; Andrea Szegedi; Éva Remenyik; Valentin Brodszky
Journal:  Qual Life Res       Date:  2021-03-08       Impact factor: 4.147

7.  Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.

Authors:  Jochen H O Hoffmann; Christian Knoop; Knut Schäkel; Alexander H Enk; Eva N Hadaschik
Journal:  Acta Derm Venereol       Date:  2021-05-25       Impact factor: 3.875

8.  Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data.

Authors:  Emilie Sbidian; Myriam Mezzarobba; Jason Shourick; Cécile Billionnet; Joël Coste; Alain Weill; Jérémie Rudant; Olivier Chosidow; Loes Hollestein; Tamar Nijsten
Journal:  Acta Derm Venereol       Date:  2021-06-22       Impact factor: 3.875

9.  Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.

Authors:  Kristin Helene Skullerud; Petter Gjersvik; Are Hugo Pripp; Erik Qvigstad; Anne Lise Ording Helgesen
Journal:  Trials       Date:  2021-07-20       Impact factor: 2.279

10.  Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.

Authors:  R B Warren; M Lebwohl; H Sofen; V Piguet; M Augustin; F Brock; F Fierens; A Blauvelt
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-17       Impact factor: 9.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.